8-K: Fennec Pharmaceuticals' PEDMARK Study Expands to Adults

Fennec Pharmaceuticals announced a new real-world study of PEDMARK for cisplatin-induced hearing loss in adolescent and adult cancer patients.

Summary

• Fennec Pharmaceuticals Inc. announced that the Tampa General Hospital Cancer Institute is initiating a study.
• The study will evaluate the real-world clinical utility of sodium thiosulfate injection (PEDMARK) in reducing the risk of ototoxicity.
• The study targets adolescent and young adult (AYA) and adult cancer patients receiving cisplatin-based chemotherapy.
• PEDMARK is currently approved for pediatric patients one month of age and older with localized non-metastatic solid tumors.
• The National Comprehensive Cancer Network (NCCN) provides a 2A recommendation for PEDMARK use in AYA patients.
• Cisplatin-induced ototoxicity affects 60-90% of patients treated with cisplatin, potentially requiring lifelong hearing aids or cochlear implants.
• PEDMARK is the first and only FDA-approved therapy for this indication in pediatric patients.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the initiation of a new study to expand PEDMARK's potential utility to a broader patient population (AYA and adults) could significantly increase its market opportunity and address a substantial unmet medical need.

Positives

• Initiation of a new real-world study expands the potential patient population for PEDMARK beyond its current pediatric approval to include adolescent and adult cancer patients.
• The study is being conducted by a reputable institution, Tampa General Hospital Cancer Institute, in collaboration with USF Health Morsani College of Medicine, lending credibility to the research.
• Real-world evidence generation is crucial for demonstrating PEDMARK's clinical utility across diverse patient populations and tumor types, potentially increasing adoption.
• PEDMARK already holds FDA approval for pediatric patients and a 2A recommendation from NCCN for AYA patients, indicating established efficacy and safety in younger populations.
• Fennec Pharmaceuticals has secured Orphan Drug Exclusivity in the U.S. and Pediatric Use Marketing Authorization in Europe, along with patent protection until 2039, providing a strong market position.

Negatives

• The filing does not contain any explicit negative statements or adverse financial results for Fennec Pharmaceuticals Inc.

Risks

• Regulatory and guideline developments may change, impacting PEDMARK's market or use.
• Scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or secure required clearances/approvals.
• Clinical results from controlled trials may not be replicated in actual patient settings, affecting real-world utility.
• Unforeseen global instability, including political instability or outbreaks of pandemic/contagious diseases (e.g., COVID-19), could impact business operations.
• Protection offered by the company's patents and patent applications may be challenged, invalidated, or circumvented by competitors.
• The available market for PEDMARK may not be as large as expected, or the product may not penetrate targeted markets effectively.
• Revenues may not be sufficient to fund further development and clinical studies.
• The company may face challenges in obtaining necessary capital when needed on acceptable terms or at all.
• Fennec may not meet its future capital requirements in different countries and municipalities.

Future Outlook

Fennec Pharmaceuticals anticipates that the real-world evidence generated from this study will play a critical role in demonstrating PEDMARK's clinical utility across diverse patient populations and tumor types. This is expected to provide clinicians with a clearer picture of PEDMARK's role in hearing loss protection for patients receiving cisplatin, potentially expanding its market impact. The company also expects future commercial and regulatory milestone and royalty payments from its licensing agreement with Norgine.

Management Comments

• Gene A. Wetzstein, PharmD, BCOP, Director of Supportive Care Research & Scientific Affairs at the TGH Cancer Institute and principal investigator, stated: "This evaluation will examine real-world clinical data and audiology monitoring that will help inform future clinical research and quality efforts in assessing, preventing and managing ototoxicity."
• Pierre S. Sayad, PhD, M.S., chief medical officer of Fennec Pharmaceuticals, commented: "Real-world evidence plays a critical role in demonstrating the clinical utility of PEDMARK across diverse patient populations and tumor types. As more institutions generate data on its use outside of controlled trials, clinicians will gain a clearer picture of the important role of PEDMARK in providing hearing loss protection for patients receiving cisplatin."

Industry Context

StockSavvy.ai notes that this announcement aligns with a broader industry trend towards generating real-world evidence (RWE) to support the expanded use of approved therapies. As healthcare systems increasingly focus on value-based care and patient outcomes, RWE studies like this one are crucial for demonstrating the practical benefits of treatments in diverse clinical settings, beyond controlled trials. This move could position PEDMARK for wider adoption in a significant patient population (AYA and adults) currently experiencing high rates of cisplatin-induced ototoxicity, addressing a critical unmet need in supportive cancer care.

Comparison to Industry Standards

• The study's focus on real-world clinical utility for cisplatin-induced ototoxicity in AYA and adult patients addresses a significant unmet need, as PEDMARK is currently the only FDA-approved preventative agent for this condition in pediatric patients.
• The collaboration with Tampa General Hospital Cancer Institute, a highly-ranked academic health system (U.S. News & World Report's 2025-2026 Best Hospitals), suggests a high standard of clinical research, comparable to leading oncology centers globally.
• The existing 2A recommendation from the National Comprehensive Cancer Network (NCCN) for AYA patients already places PEDMARK in a strong position within clinical guidelines, indicating a recognized benefit among oncology professionals, similar to other established supportive care therapies.

Stakeholder Impact

• Shareholders: Potential for increased market opportunity and revenue growth if the study demonstrates positive real-world utility in AYA and adult patients, leading to expanded use.
• Patients (AYA and Adult Cancer): Potential for a new preventative treatment to reduce the risk of permanent, irreversible hearing loss associated with life-saving cisplatin chemotherapy, significantly improving quality of life.
• Healthcare Providers: The study's findings could provide valuable real-world evidence to guide clinical practice and improve otoprotective strategies for a wider range of cancer patients.
• Regulatory Authorities: The generation of real-world evidence contributes to the understanding of PEDMARK's safety and efficacy in diverse populations, potentially supporting future label expansion.

Next Steps

• Tampa General Hospital Cancer Institute will initiate the study evaluating PEDMARK's real-world clinical utility.
• The study will examine real-world clinical data and audiology monitoring to inform future clinical research and quality efforts.
• Fennec Pharmaceuticals will continue commercialization efforts for PEDMARK/PEDMARQSI in approved markets through its partners.

Key Dates

Recommendation

The initiation of a new study for PEDMARK in a broader patient population is a positive long-term development, indicating potential for market expansion. However, this is an early-stage announcement of a study initiation, not results or a new approval. While it adds to the long-term growth narrative, it does not immediately change the company's financial fundamentals or current market position significantly enough for a 'buy' recommendation. Investors should 'hold' and monitor the progress and eventual outcomes of this real-world study, as well as the ongoing commercialization efforts in existing markets.

Keywords

PEDMARK, sodium thiosulfate, ototoxicity, cisplatin, hearing loss, cancer treatment, pediatric oncology, adolescent and young adult cancer, real-world evidence, Fennec Pharmaceuticals, Tampa General Hospital, oncology, specialty pharmaceutical